However, as mentioned above, the majority of AURKB associated pathways and miRNAs were significantly correlated with EGFR signaling pathway, and AURKB has been reported to be responsible for the therapy resistance to EGFR-TKIs in patients without secondary resistant mutations during progression, suggesting that AURKB could be a vital factor as a downstream effector of EGFR pathway contributing to tumor progression. This evidence concerns the gene AURKB and neoplasm.